Molbio Diagnostics IPO Listing Details
| Listing Date | 17th August, 2026 |
| BSE Code | 544866 |
| NSE Code | MOLBIO |
| ISIN Code | INE869T01028 |
| Offer Price | ₹768 to ₹807 |
| Face Value | ₹1 |
| Listing Price | ₹980 |
Details About Molbio Diagnostics IPO
Molbio Diagnostics received approval from SEBI for an IPO of ₹939.70 crores, including fresh issue of ₹200 crores and offer for sale up to 91,66,000 equity shares with face value of ₹1 each.
Molbio Diagnostics IPO price band is ₹768 to ₹807 per share.
Retail Individual Investors (RII):
Minimum application: 1 lot = 18 shares
Maximum application: 13 lots = 234 shares
Small High Net-worth Individuals (S-HNI):
Minimum application: 14 lots = 252 shares
Maximum application: 68 lots = 1,224 shares
Big High Net-worth Individuals (B-HNI):
Minimum application: 69 lots =1,242 shares
To invest in the Molbio Diagnostics IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,526.
- Retail investors’ (Max) investment of ₹1,88,838
- Small HNI (S-HNI): Minimum investment of ₹2,03,364.
- Small HNI (S-HNI): Maximum investment of ₹9,87,768.
- B-HNI Minimum: Minimum investment of ₹10,02,294.
Molbio Diagnostics subscription duration
Molbio Diagnostics IPO started on August 10, 2026, and closed on August 12, 2026. The investors’ allotment date was August 13, 2026, and they received a refund on August 14, 2026. The Molbio Diagnostics IPO listing date is August 17, 2026.
About Molbio Diagnostics Company
Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.
Through its wholly owned subsidiary, Bigtec Labs, Molbio has strong research and development capabilities focused on creating diagnostic platforms for point-of-care (POC) testing.
